NFA
ALXN

Nationwide Fund Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Nationwide Fund Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-181,165
Closed -$25.4M – 2561
2017
Q3 		$25.4M Sell
181,165
-8,655
-5% -$1.18M 0.1% 221
2017
Q2 		$23.1M Sell
189,820
-52,278
-22% -$6.08M 0.09% 261
2017
Q1 		$29.4M Buy
242,098
+14,819
+7% +$1.91M 0.12% 179
2016
Q4 		$27.8M Buy
227,279
+132,235
+139% +$16.2M 0.12% 188
2016
Q3 		$11.6M Sell
95,044
-1,633
-2% -$210K 0.05% 545
2016
Q2 		$11.3M Sell
96,677
-66,416
-41% -$9.42M 0.05% 528
2016
Q1 		$23.7M Sell
163,093
-18,790
-10% -$2.76M 0.1% 224
2015
Q4 		$34.7M Sell
181,883
-115,215
-39% -$20.1M 0.15% 139
2015
Q3 		$46.5M Sell
297,098
-8,984
-3% -$1.64M 0.21% 81
2015
Q2 		$55.3M Buy
306,082
+49,621
+19% +$8.56M 0.23% 74
2015
Q1 		$44.4M Sell
256,461
-22,936
-8% -$4.15M 0.18% 107
2014
Q4 		$51.7M Sell
279,397
-51
-0% -$9.45K 0.22% 75
2014
Q3 		$46.3M Sell
279,448
-32,493
-10% -$5.34M 0.2% 92
2014
Q2 		$48.7M Buy
+311,941
New +$49.3M 0.2% 94
2014
Q1 		– Sell
-327,476
Closed -$43.6M – 3231
2013
Q4 		$43.6M Buy
327,476
+12,987
+4% +$1.56M 0.18% 108
2013
Q3 		$36.5M Sell
314,489
-39,258
-11% -$4.31M 0.16% 121
2013
Q2 		$32.6M Buy
+353,747
New +$34.1M 0.17% 104

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Nationwide Fund Advisors's ALXN Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q4 2017, closing a stake of 181,165 shares — an estimated $25.4M sold.

Nationwide Fund Advisors first reported a position in ALXN in Q2 2013 and held it in 17 quarters. The position peaked at $55.3M in Q2 2015. 587 funds tracked by Wall St. Rank hold ALXN as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining Alexion Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 181,165 Alexion Pharmaceuticals shares in Q4 2017, an estimated $25.4M.
  • Nationwide Fund Advisors first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 17 quarters.
  • Nationwide Fund Advisors's Alexion Pharmaceuticals position peaked at $55.3M in Q2 2015.
  • 587 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.